Finklestein SP references, publications, articles on preclinical research, drug development, cardiac disease and preclinical drug discovery - Seth P. Finklestein M.D.

PK/PD Studies
Acute Stroke
Stroke Recovery
Intracerebral Hemorrhage
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Traumatic Brain Injury
Spinal Cord Injury
Muscular Dystrophy
Myocardial Infarction
Peripheral Vascular Disease
Others
Will Travel Services

Biotrofix References & Publications

Finklestein SP, Fanning PJ, Caday CG, Powell PP, Foster J, Clifford EM, Klagsbrun M. Increased levels of basic fibroblast growth factor (bFGF) following focal brain injury. Rest Neurol Neurosci 1990;1:387-94.

Nozaki K, Finklestein SP, Beal MF. Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats. J Cereb Blood Flow Metab 1993;13:221-8.

Nozaki K, Finklestein SP, Beal MF. Delayed administration of basic fibroblast growth factor protects against N-methyl-D-aspartate neurotoxicity in neonatal rats. Eur J Pharmacol 1993;232:295-7.

Koketsu N, Berlove DJ, Moskowitz MA, Kowall NW, Caday CG, Finklestein SP. Pretreatment with intraventricular basic fibroblast growth factor decreases infarct size following focal cerebral ischemia in rats. Ann Neurol 1994;35:451-7.

Kirschner PB, Henshaw R, Weise J, Trubetskoy V, Finklestein S, Schulz JB, Beal MF. Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. J Cereb. Blood Flow Metab 1995;15:619-23.

Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J Cereb Blood Flow Metab 1996;16:542-7.

Dietrich WD, Alonso O, Busto R, Finklestein SP. Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats. J Neurotrauma 1996;6:309-16.

Speliotes EK, Caday CG, Do T, Weise J, Kowall NW, Finklestein SP. Increased expression of basic fibroblast growth factor (bFGF) following focal cerebral infarction in the rat. Brain Res Mol Brain Res 1996;39:31-42.

Finklestein SP references, publications, articles on preclinical research, drug development, cardiac disease and preclinical drug discovery - Seth P. Finklestein M.D. Jiang N, Finklestein SP, Do T, Caday CG, Charette M, Chopp M. Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J Neurol Sci 1996;139:173-9.

Kirschner PB, Jenkins BG, Schulz JB, Finklestein SP, Matthews RT, Rosen BR, Beal MF. NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Res 1996;713:178-85.

Bethel A, Kirsch JR, Koehler RC, Finklestein SP, Traystman RJ. Intravenous basic fibroblast growth factor decreases brain injury resulting from focal ischemia in cats. Stroke 1997;28:609-15; discussion 615-6.

McDermott KL, Raghupathi R, Fernandez SC, Saatman KE, Protter AA, Finklestein SP, Sinson G, Smith DH, McIntosh TK. Delayed administration of basic fibroblast growth factor (bFGF) attenuates cognitive dysfunction following parasagittal fluid percussion brain injury in the rat. J Neurotrauma 1997;14:191-200.

Ren JM, Finklestein SP. Time window of infarct reduction by intravenous basic fibroblast growth factor following in focal cerebral ischemia. Eur J Pharmacol 1997;327:11-6.

Kawamata T, Dietrich WD, Schallert T, Gotts JE, Cocke RR, Benowitz LI, Finklestein SP. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci USA 1997;94:8179-84.

Huang Z, Chen K, Huang PL, Finklestein SP, Moskowitz MA. bFGF ameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice. Am J Physiol 1997;272:H1401-5.

Francis JW, Ren J, Warren L, Brown RH Jr, Finklestein SP. Postischemic infusion of Cu/Zn superoxide dismutase or SOD:Tet451 reduces cerebral infarction following focal ischemia/reperfusion in rats. Exp Neurol 1997;146:435-43.

Kawamata T, Ren J, Chan TC, Charette M, Finklestein SP. Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke. NeuroReport 1998;9:1441-5.

Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, Wise PM. Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 1998;18:1253-8.

Kawamata T, Ren J, Cha JH, Finklestein SP. Intracisternal antisense oligonucleotide to growth associated protein-43 blocks the recovery-promoting effects of basic fibroblast growth factor after focal stroke. Exp Neurol 1999; 158:89-96.

Upton-Rice MN, Cudkowicz ME, Warren L, Matthew RK, Ren JM, Finklestein SP, Brown RH Jr. Basic fibroblast growth factor does not prolong survival in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1999;46:934.

Finklestein SP references, publications, articles on preclinical research, drug development, cardiac disease and preclinical drug discovery - Seth P. Finklestein M.D. Ren J, Kaplan PL, Charette MF, Speller H, Finklestein SP. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke. Neuropharmacology 2000; 39:860-5.

Ay I, Sugimori H, Finklestein SP. Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Brain Res Mol Brain Res 2001; 87:71-80.

Sugimori H, Speller H, Finklestein SP. Intravenous basic fibroblast growth factor produces a persistent reduction in infarct volume following permanent focal ischemia in rats. Neurosci Lett 2001; 300:13-6.

Dijkhuizen RM, Ren J, Mandeville JB, Wu O, Ozdag FM, Moskowitz MA, Rosen BR, Finklestein SP. Functional magnetic resonance imaging of reorganization in rat brain after stroke. Proc Natl Acad Sci USA 2001, 98:12766-71.

Dijkhuizen RM, Singhal AB, Mandeville JB, Wu O, Halpern EF, Finklestein SP, Rosen BR, Lo EH. Correlation between brain reorganization, ischemic damage, and neurologic status after transient focal cerebral ischemia in rats: a functional magnetic resonance imaging study. J. Neurosci., 2003. 23: 510-517.

Wada K, Sugimori H, Bhide PG, Moskowitz MA, Finklestein SP. Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats. Stroke 2003. 34:2722-8.

Kong KY, Ren JM, Kraus M, Finklestein SP, Brown RH. Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice. Stem Cells: In Press.

Berry D, Ren JM, Kwan C-P, Sietsma DK, Sasisekharan R, Finklestein SP. Dimeric fibroblast growth factor-2 enhances functional recovery after focal cerebral ischemia. J. Rest. Neurol. Neurosci. 2005. 23: 1-6.

Ren JM, Sietsma D, Qiu S, Moessler H, Finklestein, SP. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. J. Rest. Neurol. Neurosci. 2007; 25:25-31.

Menniti FS, Ren JM, Coskran TM, Liu J, Morton D, Sietsma DK, Som A, Stephenson DT, Tate BA, Finklestein SP. PDE5A inhibitors improve functional recovery after stroke in rats: Optimized dosing regimen with implications for mechanism. J. Pharm. Exp. Therap.; 2009; 331:842-50.

Iaci JF, Ganguly A, Finklestein SP, Parry TJ, Ren J, Saha S, Sietsma DK, Srinivas M, Vecchione AM, Caggiano AO. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke. Neuropharmacology. 2010; 59:640-649.

Moore TL, Killiany RJ, Pessina MA, Moss MB, Finklestein SP, Rosene DL. Recovery from ischemia in the middle-aged brain: A nonhuman primate model. Neurobiol. Aging; 2012; 33:619-624.

Menniti FS, Ren J, Sietsma DK, Som A, Nelson FR, Stephenson DT, Tate BA, Finklestein SP. A non- brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats. Restor. Neurol. Neurosci., 2012; 30:283-289.

Home The Company Preclinical Research Services The Team News Publications Contact Us Site Map

Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.